INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 445m ago
HOUSE PTR44m ago
SEC 13F44m ago
ROBINHOOD CHAIN44m ago
Public company

IBRXImmunityBio, Inc.

CIK 0001326110

EDGAR filingsOpen in network
Disclosed transactions14
Buys / sells2 / 3
Max Insider Score29
Connections7with evidence

IBRX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
20
Lisa C. McClainRSpouse
IBRXImmunityBio, Inc.
Purchase
BUY$1,001 – $15KSep 30, 2026Oct 12, 2026
traded Sep 30, 2026
+12dHOUSE PTR

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Disclosed trade inevidence
    Lisa C. McClainPurchase disclosed 2026-10-12 · Oct 12, 2026
  • ← Lobbied forevidence
    CONTINENTAL STRATEGY, LLCLDA Q1Y 2026 first quarter · issues not listed · Aug 26, 2026
  • ← Insider ofevidence
    Simon Barry J.Director · Jun 26, 2026
24
Lisa C. McClainRSpouse
IBRXImmunityBio, Inc.
Purchase
BUY
$1,001 – $15K
Sep 28, 2026
Oct 12, 2026
traded Sep 28, 2026
+14d
HOUSE PTR

Evidence

8
SJ
Simon Barry J.Director
IBRXImmunityBio, Inc.
Open-market sale · 10b5-1 plan
SELL$197K
25.0K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

9
ML
Maxwell LindaDirector
IBRXImmunityBio, Inc.
Grant or award
A—
65.6K sh
Jun 9, 2026Jun 10, 2026
traded Jun 9, 2026
+1dSEC FORM 4

Evidence

5
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Grant or award
A—
65.6K sh
Jun 9, 2026Jun 10, 2026
traded Jun 9, 2026
+1dSEC FORM 4

Evidence

19
SC
Sachs David C.Chief Financial Officer
IBRXImmunityBio, Inc.
Tax withholding
F$296K
42.6K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

21
SC
Sachs David C.Chief Financial Officer
IBRXImmunityBio, Inc.
Option exercise
M—
82.2K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

17
SC
Sachs David C.Chief Financial Officer
IBRXImmunityBio, Inc.
Option exercise
M—
82.2K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

16
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Open-market sale · 10b5-1 plan
SELL$188K
25.0K sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

0
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Option exercise · 10b5-1 plan
M$75K
25.0K sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

3
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Option exercise · 10b5-1 plan
M—
25.0K sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

17
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Option exercise · 10b5-1 plan
M—
50.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

29
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Open-market sale · 10b5-1 plan
SELL$250K
50.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

8
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Option exercise · 10b5-1 plan
M$149K
50.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Maxwell LindaDirector · Jun 10, 2026
  • ← Insider ofevidence
    Sachs David C.Chief Financial Officer · Feb 12, 2026
  • ← Insider ofevidence
    Selecky ChristobelDirector · Jan 21, 2026

    • Lobbying

    $60K reported · de-duplicated
    2026 Q2 $0 via firms2026 Q1 $60K via firms
    • CONTINENTAL STRATEGY, LLC—2026 Q2 · posted Aug 26, 2026 ·
    • CONTINENTAL STRATEGY, LLC$60K2026 Q1 · posted Aug 26, 2026 ·

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.